Should I Buy MRM? MRM 2026 Analysis

Should You Buy Medirom Healthcare Technologies Inc (MRM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.480

1 Day change

-3.27%

52 Week Range

4.450

Analysis Updated At

2026/01/30

Not a good buy right now. Despite an extremely oversold RSI that can fuel a short-term bounce, the trend/momentum setup is still bearish (MACD histogram below zero and worsening) and there are no Intellectia buy signals, no news catalysts, and no supportive fundamentals/analyst upgrades provided to justify an immediate entry for an impatient buyer.

Technical Analysis

Pre-market: 1.59 (+3.92%), still below the pivot (1.657), suggesting price has not reclaimed a key decision level. Momentum: MACD histogram -0.0136 and negatively expanding = bearish momentum still strengthening. RSI(6) at 9.156 = deeply oversold, which often precedes a reflex bounce but is not a confirmation of trend reversal by itself. Moving averages are converging, typically indicating indecision/transition rather than a confirmed uptrend. Levels: near support S1=1.55 (then S2=1.484); resistance overhead at pivot=1.657 then R1=1.764. Pattern-based forecast: ~50% chance of -0.96% next day, but +3.55% next week and +6.73% next month—near-term chop/down risk remains. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

Technical mean-reversion potential: RSI is extremely oversold, which can trigger a sharp short-term rebound, especially if 1.55 support holds. Pre-market strength (+3.92%) hints at a possible bounce attempt. Pattern-based outlook is positive on the 1-week and 1-month horizon (+3.55%, +6.73%).

Neutral/Negative Catalysts

Trend/momentum remains bearish: MACD is below zero and deteriorating, increasing the odds that oversold conditions persist or supports break. Price is still below the pivot (1.657), so the stock has not confirmed a reversal. No news in the last week (no event-driven catalyst). Broader tape risk: S&P 500 pre-market -0.83% may pressure small caps. Trading trends: hedge funds and insiders are neutral (no supportive accumulation signal).

Financial Performance

Financial snapshot unavailable (data error: list index out of range). Latest quarter/season and growth trends cannot be assessed from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data provided, so there is no observable recent trend in upgrades/downgrades or target changes. Wall Street pro/con view cannot be validated from the dataset.

Analyst Rating

Wall Street analysts forecast MRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRM is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 1.530

Low

Averages

High